
|Videos|July 18, 2014
The Challenges of Identifying Biomarkers in Lung Cancer
Author(s)Edward S. Kim, MD
Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses some of the challenges researchers face when it comes to biomarkers in lung cancer.
Advertisement
Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses some of the challenges researchers face when it comes to biomarkers in lung cancer.
Clinical Pearls:
- Research presented at the 2014 ASCO Annual Meeting highlighted many different techniques and markers in the field of lung cancer.
- Because there are so many targeted therapies that are being developed, researchers are searching for the right biomarker in the patient to match with the targeted therapy.
- Only about 20% of lung cancer patients are covered with a biomarker that has a corresponding therapy.​
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
5










































